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Abstract
Molecular imaging of cell surface receptors can po-
tentially diagnose tumors based on their distinct ex-
pression profiles. Using multifilter spectrally resolved
optical imaging with three fluorescently labeled anti-
bodies, we simultaneously imaged three different
cell surface receptors to distinguish tumor types non-
invasively. We selected tumors overexpressing differ-
ent subtypes of EGFR receptor: HER-1 (A431) and HER-2
(NIH3T3/HER2+), or interleukin-2 receptor A-subunit
receptor (IL-2RA; SP2/Tac). After tumor establishment, a
cocktail of three fluorescently labeled monoclonal anti-
bodies was injected: cetuximab–Cy5 (targetingHER-1),
trastuzumab–Cy7(HER-2),anddaclizumab–AlexaFluor-
700 (IL-2Ra). Optical fluorescence imaging was per-
formed after 24 hours with both a red filter set and three
successive filter sets (yellow, red, and deep red).
Spectrally resolved imaging of 10 mice clearly distin-
guished A431, NIH3T3/HER2+, and SP2-Tac tumors
based on their distinct optical spectra. Three-filter sets
significantly increased the signal-to-background ratio
compared to a single-filter set by reducing the back-
ground signal, thus significantly improving the differ-
entiation of each of the receptors targeted (P < .022). In
conclusion, followingmultifilter spectrally resolved im-
aging, different tumor types can be simultaneously
distinguished and diagnosed in vivo. Multiple filter sets
increase the signal-to-noise ratio by substantially re-
ducing the background signal, and may allow more
optical dyes to be resolved within the narrow limits of
the near-infrared spectrum.
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Introduction
As new imaging modalities are developed and existing
imaging techniques continue to improve their sensitivity
and spatial resolution, imaging at the cellular level has
become a real possibility. It is hoped that these molecular
imaging techniques will play a prominent role in the field of
oncological imaging. Molecular imaging has a potential clinical
application not only for detecting tumors but also for subtyping
them based on their distinct receptor expression. As with im-
munohistochemistry, it is unlikely that a diagnosis can be made
based on a single cell surface receptor and thus, multiple cell
surface receptors must be labeled. To successfully achieve this
in vivo immunohistochemistry, the imaging modality chosen
needs to have sufficient sensitivity to detect the relatively low
number of receptors expressed on the tumor surface as well as
the ability to distinguish one receptor type from another. Of the
current clinically available imaging techniques, only positron
emission tomography and single–photon emission computed
tomography have sufficient sensitivity; however, it is difficult to
label and image each surface receptor with a characteristic ra-
dionuclide distinguishable by its emission energy with gamma
scintigraphy. Optical imaging not only offers sufficient sensi-
tivity, with the added advantages of increased spatial resolution
and absence of ionizing radiation but also allows multicolor
imaging to be performed based on the use of fluorophores with
differing emission wavelengths. However, a limitation of optical
imaging is its reduced depth penetration compared with scin-
tigraphy and magnetic resonance imaging. Optical imaging can
depict tumors anywhere in the body of mice and rats [1];
however, clinically, its application may be limited to the imaging
of either relatively superficial tumors (e.g., breast cancer) or
those accessible using the endoscope (e.g., lung, gastrointes-
tinal tract, and abdominal cavity).
We have previously developed a spectrally resolved optical
imaging technique with the ability to accurately diagnose and
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differentiate tumors based on either human epidermal growth
factor receptor type 1 (HER-1) or human epidermal growth
factor receptor type 2 (HER-2) expression [2]. This technique
used a mixture of optical agents linked to monoclonal anti-
bodies (mAbs) that directly targeted the epidermal growth
factor receptors (EGFRs) expressed by different tumor cell
lines. Spectrally resolved optical imaging with mAbs was
shown to have certain advantages over radiolabeled anti-
bodies imaged with scintigraphy; that is, the ability to identify
tumors at earlier time points, simultaneously differentiate
tumor types, partially reduce background signal, and avoid
exposure to radiation.
The EGFR family consists of four subtypes of tyrosine
kinase receptors. In normal circumstances, these receptors
play a vital regulatory role in normal cellular signaling and
development; however, mutations can lead to neoplasia.
Overexpression of EGFRs has been shown to correlate with
poor prognosis [3,4]. Antibodies to these receptors (cetux-
imab for HER-1 and trastuzumab for HER-2) have been used
clinically in selected patients. Because these agents suc-
cessfully target cancers, it is expected that, at substantially
lower doses, they could be also be used for molecular
imaging to select treatable patients with appropriate agents.
Whereas two different antibodies can be useful in char-
acterizing some tumors, it is likely that most tumors will
require more than two antibody types to be fully character-
ized. At the same time, it is important to maximize the depth
penetration of the fluorophore to be able to detect a signal
throughout a tumor. Maximal depth penetration is best
achieved with near-infrared (NIR) dyes that emit in the light
range of 650 to 900 nm. At this wavelength, hemoglobin,
muscle, and fat are least efficient in absorbing light [5];
furthermore, the autoflourescence (background) signal from
the skin is also minimal [6]. The need to use NIR dyes
means that only a limited number of separate optical probes
can be simultaneously resolved based on their individual
spectra to avoid overlap. Organic dyes have distinct narrow
excitation spectra close to their respective broad peak emis-
sion spectra, and successful resolution of more than three
dyes is technically challenging. Only nonorganic quantum
dots and the Keima series of fluorescent proteins yield
multiple emission peaks after a single excitation and offer
the potential to resolve greater numbers of optical probes.
However, in vivo imaging with the Keima proteins requires
gene transfection to induce expression using gene therapy
with viral or nonviral vectors [7,8], and is yet to be success-
fully applied to clinical practice, and quantum dots bring
with them the potential for significant toxicity based on their
Cd–Se cores, which will make their translation into the clinic
challenging [9,10].
In theory, the subtyping of selected receptors based on
markers of tumor aggressiveness could be used to guide
treatment and determine prognosis. Here, we describe the
use of three optically labeled mAbs administered as an
intravenous cocktail in mice implanted with three different
xenografts. We selected tumor cell lines expressing two
different subtypes of the same family of receptors, EGFRs,
i.e., HER-1 (A431 cells) and HER-2 (NIH3T3/HER2+ cells),
and a tumor cell line positive for a separate family of re-
ceptors, i.e., the SP2/Tac cell line, expressing the interleukin-
2 receptor alpha subunit (IL-2Ra: Tac) receptor. Imaging was
performed using the commercially available, Food and Drug
Administration (FDA)–approved mAbs cetuximab, trastuzu-
mab, and daclizumab, which specifically target the HER-1,
HER-2, and IL-2Ra (Tac) receptors, respectively.
Materials and Methods
Tumor Cells
Four established cell lineswere used: A431,NIH3T3, SP2,
and LS174T. A431 is a human epidermoid carcinoma cell line
overexpressing the HER-1 receptor, but minimally express-
ing the HER-2 receptor. NIH3T3 are murine fibroblast– like
cells that express neither HER-1 nor HER-2 receptors. The
NIH3T3 cells were transfected with HER-2 genes (NIH3T3/
HER2+) to overexpress HER-2 receptors [5]. SP2 are murine
myeloma cells. These cells were transfected with the IL-2Ra
(Tac) gene and thus are Tac- (IL-2Ra) positive (SP2/Tac).
LS174T is a human colon carcinoma cell line that is weakly
positive for HER-2 and serves as a control cell line.
A431 cell lines were cultured in Dulbecco’s modified
Eagle’s medium (Gibco, Gaithersburg, MD) containing 10%
fetal bovine serum (Gibco). NIH3T3/HER2+ cells were grown
in RPMI 1640 medium (Gibco) containing 10% fetal bovine
serum, 0.03% L-glutamine at 37jC, 100 U/ml penicillin, and
100 mg/ml streptomycin in 5% CO2.
Synthesis of Antibody-Conjugated NIR Fluorescence Dyes
Antibodies and fluorescent dyes. Erbitux, an FDA-approved
chimeric human–murine antibody specific for HER-1 recep-
tors, generically known as cetuximab, was purchased from
Bristol-Myers Squibb Company (Princeton, NJ). Herceptin, an
FDA-approved humanized anti–HER-2 antibody, generically
known as trastuzumab, which has a complimentary determi-
nation region (CDR) against HER-2 grafted on a human IgG1
framework, was purchased from Genentech Inc. (South San
Francisco, CA). Zenapax, a murine–human chimerized mAb
to the IL-2Ra (Tac) receptor of T-cells, generically known as
daclizumab, was purchased from Hoffmann-La Roche Inc.
(Nutley, NJ). AlexaFluor700 NHS ester, used for the imaging
study, and Rhodamine Green (RhodG) NHS ester, used in the
initial flow cytometry and fluorescent microscopy experiments,
were purchased from Invitrogen Corporation (Carlsbad, CA).
Cy5 NHS ester and Cy7 NHS ester were purchased from GE
Healthcare (Piscataway, NJ).
Conjugation process. At room temperature, 500 mg (3.3 nmol)
of cetuximab, trastuzumab, or daclizumab in Na2HPO4 was
incubated with 20 nmol of RhodG, 40 nmol of Cy5 NHS
ester, 30 nmol of Cy7 NHS ester, or 30 nmol of AlexaFluor700
NHS ester dissolved in 5 mM DMSO, respectively, at pH
8.5 for 15 minutes at room temperature. The mixture was
purified with a Sephadex G50 column (PD-10; GE Health-
care). Cetuximab-conjugated RhodG, trastuzumab-conjugated
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RhodG, cetuximab-conjugated Cy5, daclizumab-conjugated
AlexaFluor700, and trastuzumab-conjugated Cy7 samples
(cetuximab–RhodG, trastuzumab–RhodG, cetuximab–Cy5
and trastuzumab–Cy7, respectively) were kept at 4jC in
the refrigerator as stock solutions. The protein concentrations
of cetuximab–RhodG, trastuzumab–RhodG, cetuximab–
Cy5 and trastuzumab–Cy7 samples were determined with
Coomassie Plus protein assay kit (Pierce Biotechnology,
Rockford, IL) by measuring the absorption at 595 nm with
a UV–Vis system (8453 Value UV–Visible Value System;
Agilent Technologies, Santa Clara, CA) using standard
solutions of known concentrations of cetuximab, trastuzumab,
or daclizumab (100, 200, and 400 mg/ml). The concentrations
of RhodG, Cy5, and Cy7 were then measured by absorption
at 503, 675, and 747 nm, respectively, with the UV–Vis system
to confirm the number of fluorophore molecules conjugated
with each cetuximab, trastuzumab, or daclizumab molecule.
The number of fluorophore molecules per cetuximab, trastuzu-
mab, or daclizumab was adjusted to approximately 2.
Flow cytometry study. One-color flow cytometry studies
were performed to assess the specificity of daclizumab–
Rhodamine Green to both SP2/Tac and SP2/0 cells. Rho-
damine Green was used as a fluorescent dye because
flow cytometry is not efficient in the NIR range. In total, 1 
105 cells were placed on a 12-chamber well and incubated
for 12 hours. Daclizumab–Rhodamine Green was added
to the medium (1 mg/ml) and the cells were incubated for
72 hours. At this time point, flow cytometry was performed,
employing the argon ion 488 nm laser for excitation. Sig-
nals from cells were collected using a 530/30 nm band-pass
filter. Cells were analyzed in a FACScan cytometer (Becton
Dickinson, Franklin Lakes, NJ) and all data were analyzed
using CellQuest software (Becton Dickinson). The fluores-
cence capability of each fluorophore was referred to as the
mean fluorescence index. Fluorescence-assisted flow cy-
tometry studies following all other combinations of A431 and
NIH3T3/HER2+ cells with cetuximab–Rhodamine Green, tras-
tuzumab–Rhodamine Green, and daclizumab–Rhodamine
Green have previously been reported [2,11].
Fluorescence microscopy. In total, 1  104 SP2/TAC cells
and SP2/0 cells (negative control cells, not expressing the
IL-2Ra receptor) were plated on a coverglass-bottom culture
well and incubated for 16 hours. A conjugate of the antibody
daclizumab linked to Rhodamine Green was added to each
of the two cultured media (30 mg/ml). The cells were incu-
bated and removed at the following time points: 1, 4, 8, 24,
48, and 72 hours. Following removal, cells were washed
once with PBS and fluorescence microscopy was immedi-
ately performed using an Olympus BX61 microscope (Olym-
pus America Inc., Melville, NY) equipped with the following
filter settings: excitation wavelength = 470 to 490 nm and
emission wavelength = 515 to 550 nm. Transmitted light dif-
ferential interference contrast images were also acquired.
Fluorescencemicroscopy studies following incubation of A431
cells with cetuximab–Cy5.5 and NIH3T3/HER2+ cells with
trastuzumab–Cy7 have previously been demonstrated to be
efficacious [2]. Images were taken with a 2-second exposure.
Animal Model
All procedures were carried out in compliance with the
Guide for the Care and Use of Laboratory Animal Resources
(1996), National Research Council, and approved by the
local Animal Care and Use Committee. One from each of the
tumors A431, NIH3T3/HER2+, SP2/TAC, and LS174T was
established. For each cell line, 2 million (200 ml) cells,
suspended in PBS, were injected subcutaneously onto the
back of the mice, following intraperitoneal administration of
ketamine (90 mg/kg; Ketaset; Aveco, Inc., Fort Dodge, IA)
with xylazine (9 mg/kg; AnaSed; Lloyd, Inc., Shenandoah,
IA) as a general anesthetic. A431 cells were implanted on the
right flank, NIH3T3/HER2+ cells on the left flank, SP2/TAC on
the right shoulder, and LS174T on the left shoulder regions
(Figure W1). Tumors were monitored for growth and imaging
was undertaken when tumors reached an appropriate size
(10–14 days after implantation). In total, 20 mice were
injected with all three cell lines and, from this group, 10 mice
that grew tumors of comparable (f 5 mm) sizes were se-
lected for use in the optical imaging study.
In Vivo Spectral Fluorescence Imaging Study
Ten female nude mice (National Cancer Institute Animal
Production Facility, Frederick, MD) were implanted with
tumors (as described above). A 200-ml mixture containing
50 ml (concentration of 1 mg/ml) of each of the three antibody–
optical agent conjugates and 50 ml of PBS was prepared. The
antibody cocktail was injected intravenously through the
mouse tail vein 24 hours before optical imaging. The dosing
strategy and the decision to image at 24 hours were based
on the success of a previous work [2]. Before imaging, mice
were anesthetized with intraperitoneally administered 10%
pentobarbital sodium (Nembutal; Abbott Laboratories,
Abbott Park, IL) with 0.1% scopolamine butylbromide (Bus-
copan Injection; Nippon Boehlringer Ingelheim Co., Tokyo,
Japan). Spectral fluorescence images were obtained using
the Maestro In Vivo Imaging System (CRi Inc., Woburn, MA).
In all cases, optical image sets were acquired with both a
red filter set and three successive filter sets, i.e., yellow,
red, and deep red, for acquisition of one complete image
cube. For the yellow light filter, a band-pass filter from 575 to
605 nm and a long-pass filter of 645 nm were used for
excitation and emission light, respectively. For the red filter
set, these values were from 615 to 665 nm and 700 nm,
respectively; for the deep red filter set, the values were from
671 to 705 nm and 750 nm, respectively (Figure 1). The
tunable filter was automatically stepped in 10-nm increments
from 650 to 950 nm for the combined filter sets, whereas
the camera captured images at each wavelength interval
with constant exposure. Spectral fluorescence images
based on autofluorescence, Cy5, Cy7, and AlexaFluor700
spectra were obtained.
Spectral libraries for Cy5 and Cy7 were imported and the
respective spectra unmixed, using a commercial software
(Maestro software; CRi Inc., Woburn, MA). Specifically,
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blood pool images from non–tumor-containing regions were
unmixed from tumor-containing regions to reduce back-
ground contamination from the unbound optically labeled
antibodies. Mice were sacrificed with carbon dioxide imme-
diately after completion of imaging. Surgery was then per-
formed to resect the tumors and enable ex vivo optical
imaging, using the same Maestro settings.
Results
In Vitro Analysis
Flow cytometry studies were performed after 72 hours of
incubation of daclizumab–Rhodamine Green and either
SP2/Tac or SP2/0 cells. Daclizumab–Rhodamine Green
showed a strong binding affinity to the IL-2Ra–overexpress-
ing SP2/Tac cell, several orders of magnitude higher than the
SP2/0 (IL-2Ra–negative) control cells (Figure 2). The SP2/0
cells showed only a minimal, nonspecific binding of the
daclizumab–Rhodamine Green complex.
Fluorescence microscopy was performed for SP2/Tac
cells or for SP2/0 cells following their incubation with dacli-
zumab–Rhodamine Green. SP2/Tac cells start to show
binding of daclizumab–RhodG to the IL-2Ra receptors
expressed on their cell surface as early as 1 hour post-
incubation. With time, the complexes are gradually internal-
ized into the cell. This is initially seen by 24 hours and
becomes more apparent by the 48-hour time point when
the daclizumab–Rhodamine Green complex can clearly be
seen in the perinuclear region (Figure 3B). Control SP2/0
cells (which do not express the IL-2Ra receptor) do not
show uptake of daclizumab–Rhodamine Green at any of
the time points (Figure 3D). As with previous reports [2,11],
all antibodies showed specific binding only to their respec-
tive receptor-positive cells on in vitro analysis, except for
trastuzumab–Rhodamine Green that showed weak positive
signals from A431 cells probably because of minimal but
positive expression of HER-2 receptor on these cells.
In Vivo Imaging
To quantify our results, pixel intensity values were obtained
from each of the respective spectral images (Cy5, Cy7, and
Figure 2. FACS flow cytometry: Results for (A) SP2/Tac and (B) SP2/0 cell
lines 72 hours after incubation with antibody linked to a fluorescent dye. (A)
About 2 g/ml daclizumab (antibody to IL-2Ra receptor) linked to Rhodamine
Green, shows strong binding affinity to IL-2Ra–overexpressing SP2/Tac cells.
(B) SP2/0 cells (negative control, not expressing IL-2Ra receptors) show only
minimal, nonspecific binding of the daclizumab–Rhodamine Green.
Figure 1. Schematic representation of the multiple-filter acquisition technique.
The optical dyes Cy5, AlexaFluor700, and Cy7 have peak emissions of 694,
719, and 776 nm, respectively. Three filter sets (yellow, red, and deep red)
were used to acquire a single image cube over these wavelengths. For the
yellow light filter, a band-pass filter from 575 to 605 nm (590/30) and a long-
pass filter of 645 nm were used for excitation and emission light, respectively.
For the red filter set, these values were 615 to 665 (640/50) and 700 nm,
respectively; for the deep red filter set, the values were 671 to 705 (688/34) and
750 nm, respectively.
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AlexaFluor700) for each of the three tumors present on the
mice. Regions of interest (ROIs) were drawn around each
tumor and also on the midline region (to measure the back-
ground signal). Average pixel intensity from the tumor ROI
was divided by the average pixel intensity from the back-
ground ROI to derive a signal-to-background ratio (SBR) for
each of the three tumor types in each of the spectral ranges.
This process was repeated in each mouse for the data set
collected by the single-filter acquisition process (Table W1)
and the multifilter acquisition process (Table W2).
It is expected that NIH3T3/HER2+ tumors will bind tras-
tuzumab–Cy7, having a high SBR for Cy7 spectra, and a low
ratio (close to background) for the Cy5 and AlexaFluor700
spectra. Conversely, A431 tumors (which are targeted by
cetuximab–Cy5) should have high Cy5 SBR and low Cy7
and AlexaFluor700 values, and SP2/Tac tumors should have
high AlexaFluor700 spectra SBR, but low Cy5 and Cy7
ratios. Negative control LS174 tumors (not expressing
HER-1, HER-2, or IL-2Ra receptors) would be expected to
emit a signal consistent with background autofluorescence.
In all 10 mice, spectral fluorescence imaging was able to
differentiate A431, NIH3T3/HER2+, and SP2/Tac tumors
24 hours after injection of the antibody cocktail both in vivo
(Figure 4) and ex vivo, postresection (Figure 5). Following
the unmixing process, A431 can be seen as red, NIH3T3/
HER2+ as green, and SP2/Tac as blue. As expected, the
control LS174 tumors produced spectra consistent with the
background signal, which can be subtracted by the unmixing
process, producing a colorless appearance for these tumors.
The multiexcitation filter (yellow, red, and deep red filter)
image acquisitions (Figure 4B) generally produced much
clearer images than those obtained by a single (red) filter
(Figure 4A). This is reflected in the quantitative results,
where the multifilter acquisition data consistently produced
higher signal-to-noise ratios. Interestingly, the ex vivo–
resected tumor images do not obviously reflect the in vivo
findings. The ex vivo tumor images acquired by a single-filter
process (Figure 5A) are as clearly differentiated from one
another as with the multifilter-acquired images (Figure 5B).
This can be explained by the fact that the multifilter process
substantially reduces the background signal primarily from
the skin and blood vessels similar to that which can be
achieved by removing the tumor from the body. This can
be demonstrated in Table 1 by comparing background sig-
nals from the one-filter and the three-filter acquisition – here,
results are only displayed for each tumor type that is
expected to give the highest signal in each of the respective
spectra (i.e., A431 for Cy5, NIH3T3/HER2+ for Cy7, and
SP2/Tac for AlexaFluor700). In 29 of 30 cases (exception:
mouse 1, A431 in Cy5 spectra), the background signal was
decreased by using the three-filter acquisition. For ex vivo
images, the background signal, due either to the absence of
autofluorescence produced by the skin and/or to the ab-
sence of the blood pool effect in the skin, is not present, thus
producing images with a single filter comparable to those
obtained in vivo with a multifilter set.
We applied statistics to the signal-to-noise ratios derived
for both the single-filter and the multifilter acquisition data
sets to determine whether this apparent increase in SBR
was significant (Table 1). Using a paired nonparametric
analysis with the Wilcoxon signed rank test and comparing
each tumor-to-background signal ratio, we can demonstrate
that the use of multifilter acquisition significantly improves
the SBR for tumors. For the 10 mice imaged: three-filter
acquisition improved detection of tumors over background,
significantly increasing the signal-to-noise ratio for A431
tumors in the Cy5 spectra, average SBR increased from
48.2 (one filter) to 241.0 (three filters), P = .0215; NIH3T3/
HER2+ tumors in the Cy7 spectra, mean SBR increase
from 3.0 to 124.2 (P = .0020); and SP2/Tac tumors in
the AlexaFluor700 spectral range, SBR average increase
from 5.9 to 138.6 (P = .0215). Thus, by reducing the
background (noise), the signal of each tumor becomes more
apparent, allowing a clear distinction between the three
tumor subtypes.
Discussion
This work establishes the feasibility of using three separate
optical probes to simultaneously image receptors that are
expressed by tumor cells in vivo. Furthermore, we have
shown that the use of three different filter sets significantly
Figure 3. Fluorescence microscopy studies. (A and B) The amounts 1  104
SP2/Tac cells and (C and D) 1 104 SP2/0 cells incubated with daclizumab–
Rhodamine Green (RhodG) and viewed under fluorescence filter after 1, 4, 8,
24, 48, and 72 hours of incubation. In each case, differential interference
contrast images are shown in the left column and fluorescent light images in
the right column. SP2/Tac cells start to show binding of daclizumab–RhodG
to the IL-2Ra receptors expressed on their cell surface as early as 1 hour
postincubation. With time, the complexes are gradually internalized into the
cell with gradual perinuclear localization. Control SP2/0 cells (which do not
express the IL-2Ra receptor) do not show uptake of daclizumab–RhodG at
any of the time points. Experiments were performed on an Olympus BX61
microscope (magnification,  20) using a 2-second exposure.
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improves the signal-to-noise ratio and improves the differen-
tiation of each of the receptors targeted compared with a
single excitation. To maximize the depth penetration, NIR
wavelength fluorophores were employed on all antibodies.
Within the NIR range, we are further limited by the broad
signal peaks of the organic dyes used and the background,
autofluorescence signal, which is more prominent at the
lower end of the NIR range. Thus, the ability to image fluoro-
phores at this range is the key to increasing the number of
dyes that can be simultaneously distinguished. To this end,
we selected Cy5 (peak emission = 675 nm), AlexaFluor700
(peak emission = 723 nm), and Cy7 (peak emission = 779 nm).
The cyanine dye Cy5.5, used previously, has a peak emis-
sion of 696 nm, which is closer to that of AlexaFluor700
than Cy5, and leads to difficulties in their spectral separation
(data not shown). To obtain a more constant emission signal
from each one of these dyes, various parameters including
quantum yields of distinct dyes, efficiency of the excitation
filter, the pharmacokinetics of each antibody, and the sen-
sitivity of a charge-coupled device camera should be taken
into account. Although the dose of each antibody was fixed
at 50 mg to simplify the experiment, we were still able to
successfully distinguish distinct tumor types. The increased
signal-to-noise ratios achieved and ability to better separate
the dyes by using multiple filter sets may allow us to extend
the number of organic dyes that we can image in vivo to four
or possibly five. Another way to overcome the restrictions of
the NIR range is to use nonorganic dyes which have multiple
narrow peak emission bandwidths and require only a single
excitation light [12]; however, such dyes are not without con-
cerns over their toxicity profile, which may hinder their trans-
fer to the clinic.
The development of in vivo optical imaging with fluoro-
phores parallels the development of in vitro histopathologic
methods. Histology was originally based on simple staining
methods to identify architectural features of the specimen.
Subsequently, pathologists developed techniques to locate
molecular epitopes expressed on cells (particularly tumor
cells) using antibodies, leading to the field of immunohis-
tochemistry [13]. Similarly, the use of fluorophore-labeled
antibodies enables immunofluorescence imaging; both tech-
niques are already performed in vitro with the traditional
brightfield (light) microscope. Double or triple stains can be
used to gain more information from specimens. However,
multiple staining often cannot be performed simultaneously
and, therefore, serial sections may need to be separately pre-
pared which is disadvantageous [14]. Furthermore, with im-
munofluorescence, background signal from autofluorescence
may compromise the quality of the image [15]. Histologic
techniques using multispectral imaging have recently been
Figure 4. Multitumor in vivo spectral fluorescence imaging. Unmixed in vivo optical imaging following acquisition by (A) a single (red) filter or by (B) three (yellow,
red, and deep red) filters in the same mouse. Bold arrow, A431 tumors; arrowhead, NIH3T3/HER2+ tumors; curved arrow, SP2/Tac tumors; clear arrow, LS174T
tumors. Columns left to right demonstrate composite, Cy5 spectral, AlexaFluor700 spectral, and Cy7 spectral images, respectively. Cy5 spectral image shows
strong uptake of cetuximab–Cy5 by A431 tumors, AlexaFluor700 spectra shows high uptake by SP2/Tac tumors, and Cy7 spectral image shows increased uptake
of trastuzumab–Cy7 by NIH3T3/HER2+ tumors. The composite image (unmixing) allows differentiation of the tumors: red, A431; green, NIH3T3/HER2+; blue, SP2/
Tac. Multifilter acquisition and unmixing more clearly differentiates the tumor type, significantly increasing the signal-to-background ratios by reducing the signal
derived from autofluorescence and the blood pool effect (background).
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developed to try and overcome some of these inherent
disadvantages, by resolving multiple dyes within a single
specimen, and correcting for autofluorescence [16]. Such
techniques use similar principles to those of our in vivo op-
tical imaging technique: the use of targeted fluorophores,
acquisition of an image cube consisting of a stack of images
obtained with different band-pass filters through the visible
and NIR spectra, and subsequent spectral resolution based
on the peak emission of each dye. These methods can be
performed using either the brightfield microscopes or the
newly developed fluorescence microscopes [14]. Multicolor
immunohistochemistry methods allow exploration of molec-
ular interactions at a cellular level, a process that has been
termed molecular morphology [16]. Histology has the advan-
tage of dealing with thinly sliced ex vivo tissue, thus depth
penetration and toxicity are not issues, and nonorganic dyes
(e.g., quantum dots), with their inherent advantages, can be
used. The success of such ex vivo histologic multispectral
imaging shows the way forward for our in vivo molecular
optical imaging technique and offers insights into how best to
use such methods.
The difficulty with in vivo imaging, is the prominent
background signal arising from a combination of autofluo-
rescence from normal (nontumor) tissues and circulating,
unbound antibody–optical agent complexes within the blood
pool. When dealing with in vitro histologic samples, auto-
fluorescence from the normal tissue is not an issue and
unbound signaling agents can be washed out during prepa-
ration. When imaging in an in vivo setting, autofluorescence
is almost completely eliminated with a simple light-emitting
diode flashlight and proper narrow-bandwidth filter enabling
high-resolution, multicolor imaging of tumors in mice [17].
In contrast, the unbound injected agents, which remain in
the circulation, need to be cleared either by physiological
processes which may take considerable time or, alternatively,
by the extracorporeal circulation, i.e., immunoadsorption
[18], which introduces additional complexity and risks.
Therefore, the target-to-background signal ratio can be a
significant problem for in vivo imaging. The spectral imaging
technique using a cocktail of multiple color reagents is able to
define a distinct shape of the blood pool (background)
spectrum produced by the circulating mixed unbound
agents. The specific signal from agents that are successfully
bound to their targets can then be resolved from this back-
ground spectrum. Therefore, high background signal, pro-
duced by unbound injected agents, is much less of a problem
for this method and enables us to use intact IgG molecules
(mAbs) for targeting, despite their acknowledged prolonged
blood clearance.
A limitation of this work is that subcutaneous tumor im-
plants were employed. It is generally believed that orthotopic
implantation or genetically engineered transgenic animals
provide more realistic models [19]. However, our experi-
ments were used as a proof of principle of the targeted imag-
ing technique in vivo, and the selected cell lines are known
to express their respective antigens in both subcutaneous
Figure 5. Unmixed ex vivo optical imaging following acquisition by (A) a single (red) filter or by (B) three (yellow, red, and deep red) filters in the same mouse. Bold
arrow, A431 tumors; arrowhead, NIH3T3/HER2+ tumors; curved arrow, SP2/Tac tumors; clear arrow, LS174T tumors. Columns left to right demonstrate white light,
AlexaFluor700, composite, Cy5, Cy7 spectral images, and composite images, respectively. As with in vivo imaging, the composite image (unmixing) allows
differentiation of the tumors: red, A431; green, NIH3T3/HER2+; blue, SP2/Tac. Unmixing following both single- and multifilter acquisition produces similar results,
implying that multifilter acquisition is most useful in reducing the background (noise) signal.
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and orthotopic xenografts and so the simpler approach
was desirable. Additionally, tumors may overexpress more
than one antigen and the use of models in which only one
receptor is highly overexpressed may not be representa-
tive. Nevertheless, the technique needs to be established
before it can be refined, and further tested for ability to de-
tect smaller copies of targets and to quantify the extent
of overexpression in mixed models which will be the subject
of future studies.
In conclusion, tumors were simultaneously distinguished
and diagnosed in vivo, using a cocktail of three optically
labeled antibodies each labeled with a different fluorophore.
Multiple filter sets increased the signal-to-noise ratio by
substantially reducing the background signal, and may allow
more than three optical dyes to be resolved within the narrow
limits of the NIR range. The reduced depth penetration of
the technique would realistically limit future clinical applica-
tions to imaging either superficial tumors, or those that are
endoscopically accessible. Our technique produces high-
resolution polychromatic images and offers potential for
multicolor, multiparametric diagnosis and typing of tumors
in the clinic. Furthermore, optical imaging has the advan-
tages of sufficient sensitivity to provide semiquantitative
assessment of the number of receptors expressed on cellu-
lar surfaces and sufficient resolution to detect subsurface,
submillimeter tumors without requiring ionizing radiation.
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